

PSites Pharma GmbH

Dr. Rolf Witte

Theodor-Stern-Kai 7
60590 Frankfurt
Email: rolf.witte@psites.de
www.psites.de

PSites Pharma GmbH

The Next Generation of Protein Kinase Drugs



PSites Pharma is a biotech company focused on the development of the next generation of more specific protein kinase inhibitors. AGC kinases represent 10% of all human kinases and have a potential use for the treatment of multiple human diseases including cancer, diabetes, inflammation, neurological disorders and anti-infectives. PSites Pharma is a spinoff of the research group PhosphoSites from the University Frankfurt who, after their discovery of a specific allosteric binding site in 2000, developed and customized a whole new technology including specialized libraries, structural biology and screening platforms.

PSites Pharma GmbH is based on the original discoveries of novel regulatory, allosteric sites present in a subset of protein kinases. This know-how has led PSites Pharma GmbH to the identification of molecules that open completely novel ways to inhibit or activate signal transduction pathways. This knowledge has great potential for the development of novel drugs for treatment of diverse human diseases, with large market potential. PSites is focused on its unique platform approach to drug development to a particular site, the PIF-pocket, present in AGC protein kinases.

Competition:

All major pharmaceutical companies are engaged in the development of drugs targeting the ATP binding site on protein kinases. Nevertheless, ATP competitive compounds have severe limitations and there is a growing interest in the development of allosteric drugs. Notably, allosteric drugs may synergize and not necessarily compete with ATP competitive drugs.

However, established pharma do not have extensive experience on allosteric developments.

We note that parallel or independent validation of the PIF-pocket by competing groups within the pharmaceutical industry will strengthen the validity of our approach, decreasing apparent risks and increasing the value of our products.

Unique advantage:

PSites Pharma is based on the deep understanding of the new drug target site (the PIF-pocket), coupled with the know-how, libraries, screening and crystallography platforms specially developed for this purpose. PSites holds exclusive rights over the patents and patent applications produced at the Research Group PhosphoSites.